^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
Excerpt:
PTEN expression at baseline was higher in responders versus nonresponders (P = .042; Fig 2). Despite this, PRs were still observed in four (36%) of 11 patients with a complete loss of nuclear PTEN expression. Figure 3 shows the reduction in tumor size in patients receiving vemurafenib during BRIM-2 by PTEN expression...
DOI:
10.1200/JCO.2012.44.7888
Trial ID:
